HYBRID EVENT: You can participate in person at Singapore or Virtually from your home or work.

3rd Edition of International Conference on Probiotics and Prebiotics

March 27-29, 2025

March 27 -29, 2025 | Singapore

Probiotics in the prevention and treatment of atherosclerotic cardiovascular disease: Focus on molecular mechanisms

Speaker at Probiotics and Prebiotics 2025 - Dipak P Ramji
Cardiff University, United Kingdom
Title : Probiotics in the prevention and treatment of atherosclerotic cardiovascular disease: Focus on molecular mechanisms


Atherosclerosis, an inflammatory disorder of the vasculature and the underlying cause of myocardial infarction and cerebrovascular accidents, is responsible for more global deaths than any other disease. Although reduction in morbidity and mortality from atherosclerosis and its complications has been achieved recently by lifestyle changes and pharmaceutical intervention, this is expected to reverse in the future because of global increase in risk factors such as hypercholesterolemia, obesity, and diabetes. Current pharmaceutical therapies against atherosclerosis are associated with substantial residual risk for cardiovascular disease together with other issues such as side effects. In addition, pharmaceutical agents against many promising targets have proved disappointing at the clinical level. It is therefore essential that the molecular basis of atherosclerosis is fully understood, and new therapeutic/preventative agents or targets are identified and validated.

The major focus of recent research in my laboratory is to understand the molecular mechanisms underlying the protective anti-atherogenic actions of natural products using a combination of in vitro and in vivo model systems together with biochemical, molecular biology and immunological approaches. Our research has provided novel insights into the mechanisms underlying the protective actions of several nutraceuticals. This presentation will discuss the molecular basis of atherosclerosis, current therapies against the disease and their limitations, emerging therapies targeting lipid metabolism and the inflammatory response, and the potential of probiotic bacteria as preventative and therapeutic agents.

Audience Take Away:

  • The audience will learn about how probiotics can prevent and treat cardiovascular disease.
  • The research-led knowledge base will positively impact their jobs.
  • The research could be used other faculty to expand their research or teaching.
  • The research could impact therapeutic options available in cardiovascular disease.
  • The research could lead to development of new agents to prevent and treat heart disease.


Dipak Ramji is Professor of Cardiovascular Science and Deputy Head at the School of Biosciences in Cardiff University. He is also Fellow of the Learned Society of Wales. He received his BSc (Hons) degree (Biochemistry) and his PhD (Molecular Biology) from the University of Leeds. This was followed by post-doctoral research at EMBL (Heidelberg) and IRBM (Rome) with fellowships from the Royal Society and the EU. His current research is focused on understanding how natural products regulate cellular processes in heart disease with the goal of attaining deeper mechanistic insight and identifying preventative/therapeutic agents. He has published over 150 research articles (h index 42 and i10 index 78 with over 8670 citations), including 880 page book in 2022 on Methods in Atherosclerosis. He is an Editorial Board member of 16 international journals; regular organising committee member, speaker, and track/session chair at international conferences on heart disease; involved in grant evaluation for over 20 organisations; and supervised over 25 PhD students.